Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan

<b>Background/Objectives:</b> <i>Clostridioides difficile</i> infection (CDI) poses a significant healthcare challenge, with recurrence rates reaching 30%, leading to substantial morbidity and costs. Fidaxomicin (FDX) and bezlotoxumab (BEZ) have shown potential in reducing re...

Full description

Bibliographic Details
Published in:	Antibiotics
Main Authors:	Jun Hirai, Nobuaki Mori, Yuki Hanai, Nobuhiro Asai, Mao Hagihara, Hiroshige Mikamo
Format:	Article
Language:	English
Published:	MDPI AG 2025-02-01
Subjects:	bezlotoxumab fidaxomicin combination therapy <i>Clostridioides difficile</i> recurrence severe diarrhea
Online Access:	https://www.mdpi.com/2079-6382/14/3/228

Similar Items

Clostridioides difficile Infection: Updates on Epidemiologic Patterns, Diagnostic Tools, and Treatment Modalities
by: Lamiaa Abd El-Fattah MADKOUR
Published: (2023-07-01)

Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating <i>Clostridioides difficile</i> Infection and the Associated Recurrence Rate: A Retrospective Cohort Study
by: Nobuaki Mori, et al.
Published: (2023-08-01)

Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study
by: Marianna Meschiari, et al.
Published: (2023-06-01)

<i>Clostridioides difficile</i> Infection in an Italian Tertiary Care University Hospital: A Retrospective Analysis
by: Alice Annalisa Medaglia, et al.
Published: (2023-04-01)

The Role of Bezlotoxumab for the Prevention of Recurrent <i>Clostridioides difficile</i> Infections: A Review of the Current Literature and Paradigm Shift after 2021
by: Melanie L. Hyte, et al.
Published: (2022-09-01)

Bezlotoxumab in Patients with a Primary <i>Clostridioides difficile</i> Infection: A Literature Review
by: Guido Granata, et al.
Published: (2022-10-01)

The Risk of <i>Clostridioides difficile</i> Recurrence after Initial Treatment with Vancomycin or Fidaxomicin Utilizing Cerner Health Facts
by: Ronald G. Hall, et al.
Published: (2022-02-01)

Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Clostridioides difficile infection - An observational cohort study
by: Marcos Hernando-Gozalo, et al.
Published: (2024-05-01)

Fidaxomicin for the Treatment of <i>Clostridioides difficile</i> Infection in Adult Patients: An Update on Results from Randomized Controlled Trials
by: Daniele Roberto Giacobbe, et al.
Published: (2022-10-01)

Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of <i>Clostridioides difficile</i> Infection
by: Laura Whitney, et al.
Published: (2023-01-01)

Effect of Clostridium butyricum and antibiotics using simultaneous simple suspension in mice with Clostridioides difficile infection
by: Hideo Kato, et al.
Published: (2025-09-01)

Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
by: Alonso CD, et al.
Published: (2018-12-01)

<i>Clostridioides difficile</i> infection in hospital and community settings: summary document of a multidisciplinary group
by: Anna Danise, et al.
Published: (2024-02-01)

Inhibition of spores to prevent the recurrence of Clostridioides difficile infection - A possibility or an improbability?
by: Chun-Wei Chiu, et al.
Published: (2021-12-01)

Fidaxomicin in the treatment of colitis due to Clostridium difficile: preliminary results
by: Francesco Cortese, et al.
Published: (2014-12-01)

Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies
by: Daniele Roberto Giacobbe, et al.
Published: (2020-07-01)

<i>Clostridioides difficile</i> – a new name, the old problems with diagnosis and treatment
by: Sergey M. Zakharenko
Published: (2023-01-01)

Genetic Association Reveals Protection against Recurrence of <italic toggle="yes">Clostridium difficile</italic> Infection with Bezlotoxumab Treatment
by: Judong Shen, et al.
Published: (2020-06-01)

Is Three Company or a Crowd? Comparing and Contrasting U.S. and European <i>Clostridioides</i><i>difficile</i> Clinical Practice Guidelines
by: Jordan Jones, et al.
Published: (2022-09-01)

Modern approaches to the immunotherapy of <i>Clostridioides difficile</i>
by: K. E. Popruga, et al.
Published: (2024-01-01)

Updated Management Guidelines for <i>Clostridioides difficile</i> in Paediatrics
by: Margherita Gnocchi, et al.
Published: (2020-04-01)

Antimicrobial Resistance of <i>Clostridioides</i> (<i>Clostridium</i>) <i>difficile</i> in Cambodia
by: Lengsea Eng, et al.
Published: (2025-09-01)

Ribotypes and antimicrobial susceptibility profiles of clinical Clostridioides difficile isolates: A multicenter, laboratory-based surveillance in Taiwan, 2019–2021
by: Chin-Shiang Tsai, et al.
Published: (2024-04-01)

Biofilm Formation of <i>Clostridioides difficile</i>, Toxin Production and Alternatives to Conventional Antibiotics in the Treatment of CDI
by: Leon M. T. Dicks
Published: (2023-08-01)

Clostridium difficile colitis in an immunocompromised patient treated with fidaxomicin
by: Marcello Feasi
Published: (2015-05-01)

In vitro susceptibility of clinical Clostridioides difficile isolates in Israel to metronidazole, vancomycin, fidaxomicin, ridinilazole and ibezapolstat,
by: Orna Schwartz, et al.
Published: (2025-03-01)

A Retrospective Analysis of the Clinical Effectiveness of Tigecycline in the Treatment of <i>Clostridioides difficile</i>-Associated Diarrhea
by: Herman Joseph Johannesmeyer, et al.
Published: (2024-06-01)

Microbiota in <i>Clostridioides difficile</i>-Associated Diarrhea: Comparison in Recurrent and Non-Recurrent Infections
by: Alessandra Gazzola, et al.
Published: (2020-09-01)

Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent Clostridioides difficile infection
by: Shaodong Wei, et al.
Published: (2022-12-01)

High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China
by: Jing-Wei Cheng, et al.
Published: (2018-06-01)

Does Fidaxomicin reduce Cure and Recurrence rates compared to Vancomycin in Clostridium Difficile Infection patients?: A Systematic Review and Meta-analysis
by: Hiral N Golakiya, et al.
Published: (2022-06-01)

Approach to Clostridioides difficile diarrheal infection
by: Laura Cordes Lourenço, et al.
Published: (2025-06-01)

Decreased warfarin effects in elder with recurrent Clostridium difficile infection during fidaxomicin therapy: a case report
by: Antonio Riccardo Buonuomo, et al.
Published: (2015-03-01)

Development and validation of a clinical prediction model for Clostridioides difficile associated diarrhea
by: Ruiying Zheng, et al.
Published: (2025-05-01)

Bezlotoxumab prevents extraintestinal organ damage induced by Clostridioides difficile infection
by: Steven J. Mileto, et al.
Published: (2022-12-01)

Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD
by: L. Walsh, et al.
Published: (2024-12-01)

Clostridium difficile associated diarrhea, successfully managed with custom prepared oral vancomycin
by: JAMA Jayatilake, et al.
Published: (2022-04-01)

A roadmap for designing narrow-spectrum antibiotics targeting bacterial pathogens
by: Xinyun Cao, et al.
Published: (2022-07-01)

High Prevalence of <i>Clostridioides difficile</i> Ribotype 176 in the University Hospital in Kosice
by: Katarina Curova, et al.
Published: (2023-03-01)

Prevalence of Non-Toxigenic <i>Clostridioides difficile</i> in Diarrhoea Patients and Their Clinical Characteristics
by: Cheon-Hoo Jeon, et al.
Published: (2023-08-01)